

INIM0031: Neoplasia and its Treatment

[View Online](#)

Ajila, V., Shetty, H., Babu, S., Shetty, V., & Hegde, S. (2015). Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. *Journal of Sexually Transmitted Diseases*, 2015, 1–5. <https://doi.org/10.1155/2015/791024>

Barrett, D. M., Grupp, S. A., & June, C. H. (2015). Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. *The Journal of Immunology*, 195(3), 755–761. <https://doi.org/10.4049/jimmunol.1500751>

de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., & Plummer, M. (2012). Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology*, 13(6), 607–615. [https://doi.org/10.1016/S1470-2045\(12\)70137-7](https://doi.org/10.1016/S1470-2045(12)70137-7)

Ecker, D. M., Jones, S. D., & Levine, H. L. (2015). The therapeutic monoclonal antibody market. *mAbs*, 7(1), 9–14. <https://doi.org/10.4161/19420862.2015.989042>

Gill, S., & June, C. H. (2015). Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological Reviews*, 263(1), 68–89. <https://doi.org/10.1111/imr.12243>

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L., & June, C. H. (2013). Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. *New England Journal of Medicine*, 368(16), 1509–1518. <https://doi.org/10.1056/NEJMoa1215134>

Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. *Cell*, 100(1), 57–70. [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9)

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., ... Urban, W. J. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *New England Journal of Medicine*, 363(8), 711–723. <https://doi.org/10.1056/NEJMoa1003466>

Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2015). DNA repair, genome stability and cancer: a historical perspective. *Nature Reviews Cancer*, 16(1), 35–42. <https://doi.org/10.1038/nrc.2015.4>

Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. *Nature Reviews Drug Discovery*, 14(9), 642–662.

<https://doi.org/10.1038/nrd4663>

Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016). Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine*, 22(1), 26–36. <https://doi.org/10.1038/nm.4015>

Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. *Nature*, 450(7171), 903–907. <https://doi.org/10.1038/nature06309>

Larson, C., Oronsky, B., Scicinski, J., Fanger, G. R., Stirn, M., Oronsky, A., & Reid, T. R. (2015). Going viral: a review of replication-selective oncolytic adenoviruses. *Oncotarget*, 6(24). <https://doi.org/10.18632/oncotarget.5116>

Lazebnik, Y. (2010). What are the hallmarks of cancer? *Nature Reviews Cancer*, 10(4), 232–233. <https://doi.org/10.1038/nrc2827>

Lingyun Geng. (2015). Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. *International Journal of Clinical and Experimental Medicine*, 8(9). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/>

Matsuoka, M., & Jeang, K.-T. (2011). Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene*, 30(12), 1379–1389. <https://doi.org/10.1038/onc.2010.537>

Morris, E. C., & Stauss, H. J. (2016). Optimizing T-cell receptor gene therapy for hematologic malignancies. *Blood*, 127(26), 3305–3311. <https://doi.org/10.1182/blood-2015-11-629071>

Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer*, 12(4), 265–277. <https://doi.org/10.1038/nrc3258>

Pierangeli, A., Antonelli, G., & Gentile, G. (2015). Immunodeficiency-associated viral oncogenesis. *Clinical Microbiology and Infection*, 21(11), 975–983. <https://doi.org/10.1016/j.cmi.2015.07.009>

Reichert, J. M. (2012). Marketed therapeutic antibodies compendium. *mAbs*, 4(3), 413–415. <https://doi.org/10.4161/mabs.19931>

Reichert, J. M. (2016). Antibodies to watch in 2016. *mAbs*, 8(2), 197–204. <https://doi.org/10.1080/19420862.2015.1125583>

Reichert, J. M. (2017). Antibodies to watch in 2017. *mAbs*, 9(2), 167–181. <https://doi.org/10.1080/19420862.2016.1269580>

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. *Nature Reviews Immunology*, 12(4), 269–281. <https://doi.org/10.1038/nri3191>

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M., Lee, C.-C. R., Levy, C. L., Li, Y. F., El-Gamil, M., Schwarz, S. L., ...

Rosenberg, S. A. (2011). Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. *Journal of Clinical Oncology*, 29(7), 917–924. <https://doi.org/10.1200/JCO.2010.32.2537>

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. (2011). Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. *Science*, 331(6024), 1565–1570. http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents

Roos, W. P., Thomas, A. D., & Kaina, B. (2015). DNA damage and the balance between survival and death in cancer biology. *Nature Reviews Cancer*, 16(1), 20–33. <https://doi.org/10.1038/nrc.2015.2>

Russell, S. J., Peng, K.-W., & Bell, J. C. (2012). Oncolytic virotherapy. *Nature Biotechnology*, 30(7), 658–670. <https://doi.org/10.1038/nbt.2287>

Schinzari, V., Barnaba, V., & Piconese, S. (2015). Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. *Clinical Microbiology and Infection*, 21(11), 969–974. <https://doi.org/10.1016/j.cmi.2015.06.026>

Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. *Science*, 348(6230), 69–74. <https://doi.org/10.1126/science.aaa4971>

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001). IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature*, 410(6832), 1107–1111. <https://doi.org/10.1038/35074122>

Spurgeon, M. E., & Lambert, P. F. (2013). Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. *Virology*, 435(1), 118–130. <https://doi.org/10.1016/j.virol.2012.09.029>

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., ... Sznol, M. (2012). Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New England Journal of Medicine*, 366(26), 2443–2454. <https://doi.org/10.1056/NEJMoa1200690>

Varghese, S., & Rabkin, S. D. (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. *Cancer Gene Therapy*, 9(12), 967–978. <https://doi.org/10.1038/sj.cgt.7700537>

Weinberg, R. A. (2014). *The biology of cancer* (2nd ed). Garland Science.

Weiss, R. A., & Vogt, P. K. (2011). 100 years of Rous sarcoma virus. *The Journal of Experimental Medicine*, 208(12), 2351–2355. <https://doi.org/10.1084/jem.20112160>

Wendzicki, J. A., Moore, P. S., & Chang, Y. (2015). Large T and small T antigens of Merkel cell polyomavirus. *Current Opinion in Virology*, 11, 38–43. <https://doi.org/10.1016/j.coviro.2015.01.009>

zur Hausen, H. (2009). Papillomaviruses in the causation of human cancers — a brief

historical account. *Virology*, 384(2), 260–265. <https://doi.org/10.1016/j.virol.2008.11.046>